Article

Electrical Mapping to Optimise Heart Failure Outcomes Following Cardiac Resynchronisation Therapy

Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
Information image
Average (ratings)
No ratings
Your rating

Abstract

Cardiac resynchronisation therapy (CRT) using biventricular pacing is an established therapy for impairment of left ventricular (LV) systolic function in patients with heart failure (HF). Although technological advances have improved outcomes in patients undergoing biventricular pacing, the optimal placement of pacing leads remains challenging, and approximately one third of patients have no response to CRT. This may be due to patient selection and lead placement. Electrical mapping can greatly improve outcomes in CRT and increase the number of patients who derive benefit from the procedure. MultiPoint™ pacing (St Jude Medical, St Paul, MN, US) using a quadripolar lead increases the possibility of finding the best pacing site. In clinical studies, use of MultiPoint pacing in HF patients undergoing CRT has been associated with haemodynamic and clinical benefits compared with conventional biventricular pacing, and these benefits have been sustained at 12 months. This article describes the proceedings of a satellite symposium held at the European Heart Rhythm Association (EHRA) Europace conference held in Milan, Italy, in June 2015.

Keywords

Heart failure, cardiac resynchronisation, MultiPoint pacing,

Disclosure:Dr Curnis has received fees from Medtronic Inc, Biotronik,St Jude Medical, Boston Scientific, Sorin Liva Nova and Spectranetics; Dr O’Donnell has received fellowship support from Medtronic Inc and St Jude Medical, advisory booard fees from St Jude Medical and Metronic and speakers fees from Medtronic Inc, St Jude Medical, Boston Scientific, Boehringer Ingelheim and Merit Medical; Dr Kloppe has received consulting fees from Medtronic Inc and St Jude Medical, and lecture fees from Medtronic Inc, Boston Scientific and St. Jude Medical; Dr Calovic has received speakers fees from St Jude Medical

Received:

Accepted:

Published online:

DOI:https://doi.org/10.15420/aer.2015.4.3.S1

Support:This supplement is based on the proceedings of a St Jude Medical satellite symposium held at the EHRA Europace conference, Milan, Italy in June 2015. This report was written by a medical writer, Katrina Mountfort, and the participants all reviewed and approved this supplement before publication. St Jude Medical reviewed the supplement for technical accuracy and sponsored the development of this supplement in Arrhythmia & Electrophysiology Review.

Copyright Statement:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

Dr O’Donnell began by stating that the response to CRT is suboptimal and a significant proportion of the poor response to CRT is due to poor positioning of the LV leads. In a typical left bundle branch block (LBBB), the response to routine CRT is 60 to 70 %, with an 8 % improvement in EF. Most physicians consider this a good response rate. However, if CRT is electrically mapped, outcomes can be further improved to yield an 80 % response rate and 12 % improvement in EF.

In order to improve CRT outcomes, we need to consider the factors that influence the response. These include patient selection: an increasingly smaller group are becoming eligible for CRT, meaning that a significant number of patients with HF are missing out on a treatment that may benefit them. Prior to electrical mapping, patients with atypical LBBB had a poor chance of responding to CRT. Randomised studies show response rates of around 40 % and EF improvements of 3%. Electrically mapped CRT nearly doubles the response in these patients (response rate 75 % and an 11 % improvement in EF).6

Patients with other conduction abnormalities, including a narrow QRS, right bundle branch block (RBBB) and non-specific IVCDs (NIVCD) have also typically been excluded from CRT. Many consider that traditional CRT is ineffective for these patients; in cases of narrow QRS, response rate is negligible with no improvement in EF.7 However, with electrically mapped CRT, the response rate is 65 % and the EF improves by 8 %. The same is true of RBBB/NIVCD, where electrically mapped CRT can give responses of 60 % with an EF improvement of 6 %.8

Correct lead placement is also essential to optimise responses to CRT. Dr O’Donnell explained the challenges of optimising myocardial cell-to-cell transmission in CRT using the analogy of transmitting a message to a group of soldiers in such a way that each soldier receives the message as quickly as possible. However, CRT presents unique challenges such as scar (some soldiers do not pass on the message); conduction block (some soldiers only pass the message in one direction); functional block (some soldiers pass the message slowly or incompletely); and intrinsic conduction (some soldiers utilise intrinsic communication systems).

In other words, we need to focus on where to put the leads, the electrical conduction and the electrical map. In the same way that golf clubs and tennis racquets have a ‘sweet spot’ for an optimal shot, Dr O’Donnell suggested that there is a sweet spot in CRT. However, at present, we do not know where or how big it is. The remarkable improvement experienced by some patients with anterior leads suggests that in some people, the sweet spot is clearly bigger than others and in a broad left bundle with notching, it may be 2 to 3 cm, and the lead positioning is less crucial; whereas in cases of narrow QRS, it may be as small as 2 mm. This raises the questions: how close do we have to place the leads to achieve 90 % of the effect? If we do not find the right spot, are we making these patients worse? Large studies suggest that 10 to 15 % of patients deteriorate following CRT.9

Dr O’Donnell presented his ideas as a series of concepts. Concept 1 is that there are better and there are worse places to pace in the heart. Others argue that this is incorrect and support their arguments with data that show the LV lead location does not impact on mortality or measures of response to CRT.10 Interpretations of the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) data have also led to the conclusion that the lead position is unimportant.11 However, this study concluded that, anatomically, it is difficult to determine where to put the lead, but areas of scar or the apical region should be avoided. This leads to Concept 2: anatomical placement is ineffective for finding the sweet spot. Therefore, if the sweet spot exists, it must be electrical. The reasons that anatomical placement fails is evident if we look at the different forms of septal activation in LBBB – a slide was presented of 20 different anatomical specimens of LBBB in 20 different patients – so it is unreasonable to expect that placing the lead in the same position in everyone will be beneficial.

A study of electrical activation in LBBB shows that there are multiple types of activation, and most people consider the typical LB that travels down the septum in a U shape but this activation pattern occurs in less than 50 % of all LBBB.12 A recent study of patients with LBBB found that the type of bundle block significantly influences response to CRT; an absence of ECG markers of residual LB conduction was predictive of a greater improvement in LV function with CRT.6

A study found that markers of electrical dyssynchrony, including the electrical delay at the LV pacing site (QLV) are predictive of response to CRT. Activation was measured as the time that the intrinsic electrical wave front detected in the RV lead takes to travel to the LV lead,8 a simple process that takes only seconds. If RV and LV electrograms are on time with each other, it is difficult to resynchronise the entire area effectively. Such patients are termed non-responders. In a typical non-responder, intrinsic RV–LV = 20 ms, QRSd = 145 ms, QLV = 15 %. In a typical responder intrinsic RV–LV = 120 ms, QRSd = 145 ms, QLV = 82 %, i.e., a large electrical delay. There was moderate correlation between intrinsic RV–LV electrical delay and delta LV versus absolute change in LVEF (p=0.03).8

Many groups have validated this study. Electrical delay in the LV lead has been shown to be correlated with the haemodynamic response to CRT expressed as an intra-individual percentage change in the maximum rate of rise of LV pressure over baseline (dP/dt, derived from the mitral regurgitation Doppler profile).13–15 Later activated areas are associated with higher stroke volume16 and improved LV synchrony as determined by tissue Doppler imaging (TDI).17 The seminal electrical mapping study by Gold et al. found that a measured QLV interval is an electrical marker of delayed LV lead position and that long QLV is associated with better echocardiogram and clinical outcomes.18 The LV end-systolic volume and quality of life (QOL) response rates were statistically significant in the QLV quartiles used.

Another study examined the impact of electrical and anatomical location of the LV lead in relation to baseline QRS morphology on the CRT outcome.19 The best response was seen in a patient with an LB and an LV lead late in the QRS complex. Interestingly, patients with a non-left bundle and a narrow QRS had a similar benefit if the lead was placed in the correct spot. In other words, there is a statistical difference between having the wrong patient with the lead in the right spot and the right patient with the lead in the wrong spot. It can therefore be concluded that patient selection is important for successful outcomes in CRT, but it is only one component of a complex picture.

In the Targeted Left Ventricular Lead Placement to Guide Cardiac Resynchronization Therapy (TARGET) study, patients (n=220) underwent baseline echocardiographic speckle-tracking two-dimensional radial strain imaging and were then randomised 1:1 into two groups. In group 1 (TARGET), the LV lead was positioned at the latest site of peak contraction that was free from scar and non-apical. Group 2 (control) patients underwent standard unguided CRT. Patients were classified by the relationship of the LV lead to the optimal site as concordant (at optimal site), adjacent (within 1 segment), or remote (≥2 segments away). The primary endpoint was a 15 % reduction in LV end-systolic volume at 6 months. Secondary endpoints were clinical response (one improvement in NYHA functional class), all-cause mortality and combined all-cause mortality and HF-related hospitalisation. Response rates were higher in TARGET patients (83 % versus 65 %; p=0.003), and superior improvements in ESV and QOL were also reported.20 The major finding of this study was the importance of lead placement exactly at the latest zone, not merely adjacent to the latest zone (see Figure 1). These study data can be summarised in Concept 3: electrical mapping is effective and improves outcomes for patients undergoing CRT.

Dr O’Donnell proceeded to describe how electrical mapping is used in his institution: following lead placement, activation is measured from proximal to distal, which shows an activation wave front. By using the electrical map to achieve a more distal lead placement, improvements can be gained. In the ongoing ‘moving the LV lead quad lead’ study, in patients where the lead was moved, QLV at final position was 89 % whereas in patients where the lead was not moved, QLV in final position was 77 %,21 leading to Concept 3b; electrical mapping is effective and improves outcomes for patients undergoing CRT. However, electrical mapping requires moving the lead if it is not in the late zone.

There is a reluctance among cardiologists to move leads and, in these situations, a quadripolar lead is useful. A recent multicentre study of consecutive implants and a quadripolar lead has shown that the mean difference in intrinsic electrical activation of the usable electrodes was 30 ms (3 to 55 ms). Quadripolar leads reduce phrenic nerve stimulation, reduce high thresholds and are user friendly; however, the most compelling argument for their use is the fact that resynchronisation parameters can be improved by 20 ms by picking the best versus worst electrode.

The optimal pacing site appears to be determined by the fastest pathway of activation from the LV and RV electrodes.22 If it takes longer to move from one side of the heart than from another, the answer is to move the leads. The greater the difference in timings left–right versus right–left, the worse the outcomes, i.e., delta LV. In a recent study, the RV-paced delay (RVp-LV) and LV-paced delay (LVp-RV) were measured during RV-only pacing and LV-only pacing, respectively. The timing difference between the LVp-RV and RVp-LV was termed the delta LV. Results showed that significant intrinsic electrical delay and shorter delta-LV both predicted response, even when LV leads were implanted in the targeted mechanically delayed segment. Such assessments of electrical dyssynchrony may be used to determine optimal lead positions and response to CRT.23

TARGET Study – Combined Endpoint of Death and Heart Failure-related Hospitalisation According to Left Ventricular Lead Position

Article image
Download

In conclusion, electrical mapping is very effective but is not yet easy. Anatomical LV lead placement does not enable optimal patient outcomes but electrical mapping can guide LV placement and improve outcomes for patients undergoing CRT. Increased experience will improve our expertise at mapping CRT. However, by using the lead with the most poles and the device with the most programming options, we can future proof our patients.

References

  1. Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/ HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2013;61:e6–75.
  2. Bristow MR, Saxon LA, Boehmer J, et al. Cardiacresynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140–50.
  3. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539–49.
  4. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329–38.
  5. Curtis AB, Yancy CW, Albert NM, et al. Cardiac resynchronization therapy utilization for heart failure: findings from IMPROVE HF. Am Heart J 2009;158:956–64.
  6. Perrin MJ, Green MS, Redpath CJ, et al. Greater response to cardiac resynchronization therapy in patients with true complete left bundle branch block: a PREDICT substudy. Europace 2012;14:690–5.
  7. Zareba W, Klein H, Cygankiewicz I, et al. Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial- Cardiac Resynchronization Therapy (MADIT-CRT). Circulation 2011;123:1061–72.
  8. O‘Donnell D, Lin T, Swale M, et al. Long-term clinical response to cardiac resynchronisation therapy under a multidisciplinary model. Intern Med J 2013;43:1216–23.
  9. Ploux S, Eschalier R, Whinnett ZI, et al. Electrical dyssynchrony induced by biventricular pacing: implications for patient selection and therapy improvement. Heart Rhythm 2015;12:782–91.
  10. Saxon LA, Olshansky B, Volosin K, et al. Influence of left ventricular lead location on outcomes in the COMPANION study. J Cardiovasc Electrophysiol 2009;20:764–8.
  11. Singh JP, Klein HU, Huang DT, et al. Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial. Circulation 2011;123:1159–66.
  12. Regoli F, Auricchio A. The role of invasive mapping in the electrophysiology laboratory. Europace 2009;11(Suppl. 5):v40–5.
  13. Singh JP, Fan D, Heist EK, et al. Left ventricular lead electrical delay predicts response to cardiac resynchronization therapy. Heart Rhythm 2006;3:1285–92.
  14. Zanon F, Baracca E, Pastore G, et al. Determination of the longest intrapatient left ventricular electrical delay may predict acute hemodynamic improvement in patients after cardiac resynchronization therapy. Circ Arrhythm Electrophysiol 2014;7:377–83.
  15. Gold MR, Leman RB, Wold N, et al. The effect of left ventricular electrical delay on the acute hemodynamic response with cardiac resynchronization therapy. J Cardiovasc Electrophysiol 2014;25:624–30.
  16. van Geldorp IE, Delhaas T, Hermans B, et al. Comparison of a non-invasive arterial pulse contour technique and echo Doppler aorta velocity-time integral on stroke volume changes in optimization of cardiac resynchronization therapy. Europace 2011;13:87–95.
  17. Lane RE, Chow AW, Mayet J, et al. The interaction of interventricular pacing intervals and left ventricular lead position during temporary biventricular pacing evaluated by tissue Doppler imaging. Heart 2007;93:1426–32.
  18. Gold MR, Birgersdotter-Green U, Singh JP, et al. The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronization therapy. Eur Heart J 2011;32:2516–24.
  19. Kandala J, Upadhyay GA, Altman RK, et al. QRS morphology, left ventricular lead location, and clinical outcome in patients receiving cardiac resynchronization therapy. Eur Heart J 2013;34:2252–62.
  20. Khan FZ, Virdee MS, Palmer CR, et al. Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial. J Am Coll Cardiol 2012;59:1509–18.
  21. Lin T, Crosby P, Sugumar H, et al. Implant electrical characteristics predict response to cardiac resynchronization therapy, WJCD, 2014;4:513–21.
  22. Mafi Rad M, Blaauw Y, Debie L, et al. Evaluation of left ventricular endocardial cardiac resynchronization therapy in a non-responder with ventricular arrhythmias, Indian Pacing Electrophysiol J, 2014;14:32–6.
  23. Leclercq C, Gadler F, Kranig W, et al. A randomized comparison of triple-site versus dual-site ventricular stimulation in patients with congestive heart failure. J Am Coll Cardiol 2008;51:1455–62.
  24. Thibault B, Dubuc M, Khairy P, et al. Acute haemodynamic comparison of multisite and biventricular pacing with a quadripolar left ventricular lead. Europace 2013;15:984–91.
  25. Rinaldi CA, Leclercq C, Kranig W, et al. Improvement in acute contractility and hemodynamics with multipoint pacing via a left ventricular quadripolar pacing lead. J Interv Card Electrophysiol 2014;40:75–80.
  26. Pappone C, Calovic Z, Vicedomini G, et al. Multipoint left ventricular pacing improves acute hemodynamic response assessed with pressure-volume loops in cardiac resynchronization therapy patients. Heart Rhythm 2014;11:394–401.
  27. Pappone C, Calovic Z, Vicedomini G, et al. Multipoint left ventricular pacing in a single coronary sinus branch improves mid-term echocardiographic and clinical response to cardiac resynchronization therapy. J Cardiovasc Electrophysiol 2015;26:58–63.
  28. Zanon F, Baracca E, Pastore G, et al. Multipoint pacing by a left ventricular quadripolar lead improves the acute hemodynamic response to CRT compared with conventional biventricular pacing at any site. Heart Rhythm 2015;12:975–81.
  29. Forleo GB, Santini L, Potenza D, et al. Impact of multi-point left ventricular pacing on QRS duration and left ventricular ejection fraction. Preliminary results from a multicenter prospective study. Presented at HRS, Boston, May 2015 Abstract no p004-183.
  30. Fornwalt BK, Sprague WW, BeDell P, et al. Agreement is poor among current criteria used to define response to cardiac resynchronization therapy. Circulation 2010;121:1985–91.
  31. Abraham WT. Results from the FREEDOM Trial – Assess the Safety and Efficacy of Frequent Optimization of Cardiac Resynchronization Therapy. SP08. Late-Breaking Clinical Trials, HRS 2010. Denver, Colorado, US.
  32. Ellenbogen KA, Gold MR, Meyer TE, et al. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation 2010;122:2660–8.
  33. Pappone C, Rosanio S, Oreto G, et al. Cardiac pacing in heart failure patients with left bundle branch block: impact of pacing site for optimizing left ventricular resynchronization. Ital Heart J 2000;1:464–9.
  34. Shetty AK, Sohal M, Chen Z, et al. A comparison of left ventricular endocardial, multisite, and multipolar epicardial cardiac resynchronization: an acute haemodynamic and electroanatomical study. Europace 2014;16:873–9.
  35. Thibault B, Dubuc M, Karst E, et al. Design of an acute dP/ dt hemodynamic measurement protocol to isolate cardiac effect of pacing. J Card Fail 2014;20:365-72.
  36. Rinaldi CA, Kranig W, Leclercq C, et al. Acute effects of multisite left ventricular pacing on mechanical dyssynchrony in patients receiving cardiac resynchronization therapy. J Card Fail 2013;19:731-8.
  37. Pappone C, Calovic Z, Vicedomini G, et al. Improving cardiac resynchronization therapy response with multipoint left ventricular pacing: Twelve-month follow-up study. Heart Rhythm 2015;12:1250–8.
  38. Pappone A, Calovic Z, Cuko A, et al. Multipoint left ventricular pacing provides additional echocardiographic benefit to responders and non-responders to conventional cardiac resynchronization therapy. Eur Heart J 2015; Suppl A: A12-A17.
Next Volume Article